Subject(s)
Atherosclerosis/prevention & control , Coronary Artery Disease/prevention & control , Guidelines as Topic , Adrenergic beta-Antagonists/therapeutic use , American Heart Association , Atherosclerosis/mortality , Coronary Artery Disease/mortality , Developed Countries , Developing Countries , Global Health , Health Planning Organizations/standards , Humans , Morbidity , Tobacco Use Cessation , United StatesABSTRACT
BACKGROUND1.1. The importance of secondary cardiovascular preventionEvery year, around 35 million people have an acute coronary or cerebrovascular event. About one quarter of these events occur in individuals with known atheroscleroticvascular disease. The number of people with prevalent cardiovascular disease (CVD) worldwide is likely to be around 100 million [1e3]. The five-year rateof recurrent myocardial infarction, stroke, heart failure orcardiovascular death among patients with known CVD is between 20% and 30%, which has been estimated to befour to five times greater than the rate among moderateand high-risk individuals without known CVD [4]. Such individuals are eligible for secondary preventive therapie...
Subject(s)
Atherosclerosis , Cardiovascular Diseases , Cardiovascular Diseases/prevention & control , Carotid Artery DiseasesABSTRACT
Every year, around 35 million people have an acutecoronary or cerebrovascular event. About one quarter ofthese events occur in individuals with known atheroscleroticvascular disease. The number of people withprevalent cardiovascular disease (CVD) worldwide islikely to be around 100 million [1e3]. The five-year rateof recurrent myocardial infarction, stroke, heart failure orcardiovascular death among patients with known CVD isbetween 20% and 30%, which has been estimated to befour to five times greater than the rate among moderateandhigh-risk individuals without known CVD [4]. Suchindividuals are eligible for secondary preventive therapies...
